PA
TARS icon

Profund Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Profund Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Buy
4,993
+971
+24% +$62K 0.01% 770
2026
Q1 		$282K Buy
4,022
+192
+5% +$13.4K 0.01% 788
2025
Q4 		$314K Sell
3,830
-2,318
-38% -$173K 0.01% 838
2025
Q3 		$365K Sell
6,148
-3,321
-35% -$163K 0.01% 646
2025
Q2 		$384K Buy
9,469
+1,064
+13% +$47.9K 0.01% 561
2025
Q1 		$432K Sell
8,405
-31
-0.4% -$1.53K 0.02% 521
2024
Q4 		$467K Sell
8,436
-265
-3% -$12K 0.02% 555
2024
Q3 		$286K Sell
8,701
-425
-5% -$11.9K 0.01% 830
2024
Q2 		$248K Buy
9,126
+1,929
+27% +$64.9K 0.01% 842
2024
Q1 		$262K Buy
+7,197
New +$212K 0.01% 927

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Profund Advisors's TARS Position: Q2 2026 in Review

Profund Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 24% in Q2 2026, buying an estimated $62K and bringing the position to 4,993 shares worth $314K. The position accounts for 0.01% of the portfolio, ranked #770.

Profund Advisors first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $467K in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Profund Advisors held 4,993 shares of Tarsus Pharmaceuticals worth $314K as of Q2 2026.
  • Profund Advisors bought 971 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $62K.
  • Tarsus Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #770 holding.
  • Profund Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Profund Advisors's Tarsus Pharmaceuticals position peaked at $467K in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.